NCT03189043

Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10,000 (estimated)
• Sponsor: Aionx, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a controlled open label efficacy study of Aionx antimicrobial surface for the prevention of healthcare-associated infections.

Detailed description

The study is an open label controlled efficacy trial of Aionx patented antimicrobial surface for the prevention of healthcare-associated infections (HAIs). It will take place at Penn State Hershey. Half of the single occupancy rooms of the 5th and 7th floor will be assigned to contain the antimicrobial surface at five locations: bed rails, overbed table, door handles, counter, and arm rests of bedside chair. The remaining rooms will serve as controls. Data on HAIs will be gathered for all the patients admitted to the rooms during the duration of the study. After 45 days the rooms will be flipped so that test rooms become controls and control rooms become test rooms. The duration of the study will be for a minimum of 90 days.

Conditions

• Healthcare Associated Infection

Interventions

Type	Name	Description
DEVICE	Antimicrobial Surface	Antimicrobial Surface

Timeline

• Start date: 2017-07-01
• Primary completion: 2017-10-01
• Completion: 2017-10-01
• First posted: 2017-06-16
• Last updated: 2017-06-16